2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
7
Neoplasms
3
Lung Neoplasms
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion
1
Pituitary Diseases
1
Pituitary ACTH Hypersecretion
1
Obesity
1
Myasthenia Gravis
1
Motor Activity
1
Lymphoma
1
Kidney Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Cardiotoxicity
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Advanced Solid Tumors
1
Adenocarcinoma of Lung
1
ACTH-Secreting Pituitary Adenoma
1
Interventions
Gemcitabine
113
Cisplatin
77
Oxaliplatin
46
pembrolizumab
35
Fluorouracil
33
Capecitabine
31
durvalumab
27
Leucovorin
27
lenvatinib
26
Magnetic Resonance Spectroscopy
15
Irinotecan
14
Drug Therapy
13
Biopsy
13
Nivolumab
12
Albumin-Bound Paclitaxel
12
tislelizumab
11
Specimen Handling
11
Radiofrequency Ablation
11
130-nm albumin-bound paclitaxel
11
pemigatinib
10
apatinib
10
Taxes
10
Radiotherapy
10
Floxuridine
10
Folfox protocol
9
Bevacizumab
9
S 1 (combination)
8
Platinum
8
Photochemotherapy
8
Liver Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Biomarkers
×
Clear all
NCT02893085
2016-12-28
ONCOBIL
CHU de Reims
Completed
100 enrolled